Spyglass Pharma (SGP) is now covered by HC Wainwright. They set a "buy" rating and a $37.00 price target on the stock.
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System [Yahoo! Finance]
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
Spyglass Pharma (SGP) was upgraded by Zacks Research to "hold".
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit [Yahoo! Finance]